Qu Biologics’ scientific team is exploring the treatment of Crohn’s disease and other immune-related diseases by focusing on the underlying source of the chronic inflammation: a deficiency in innate immune system function. Qu Biologics’ working hypothesis is that Crohn’s disease and other immune-related diseases are caused by an inability of a particular type of white blood cell, the macrophage, to effectively clear damaged or infected cells. If damaged or infected cells are not efficiently removed by macrophages, they become necrotic and release their contents into the surrounding tissue and/or blood vessels. The body then responds by generating an adaptive immune response against these cellular components, resulting in chronic inflammation in the affected tissue(s).
In order to break this self-sustaining cycle and effectively treat the underlying cause of Crohn’s disease, the source of this chronic inflammation must be cleared. Qu Biologics is exploring whether this can be achieved by treatment with SSIs, Qu Biologics’ proprietary immunomodulation therapy platform. Qu Biologics has demonstrated in animal models that SSIs, derived from inactivated bacterial preparations, initiate an immune response in the organ/tissue in which the bacterial species commonly causes infection. Based on this preliminary data in animals, it is believed possible that an SSI derived from a bacteria commonly found in the gut may stimulate an immune response in the colon and gastrointestinal tract, potentially resulting in marked recruitment of new macrophages to the colon which could clear the self-antigen that is triggering the chronic inflammatory response. Qu Biologics hypothesizes that once this underlying source of inflammation is cleared, the symptoms characteristic of the immune-related disease being treated will resolve.